JP7471291B2 - 関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体 - Google Patents
関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体 Download PDFInfo
- Publication number
- JP7471291B2 JP7471291B2 JP2021525229A JP2021525229A JP7471291B2 JP 7471291 B2 JP7471291 B2 JP 7471291B2 JP 2021525229 A JP2021525229 A JP 2021525229A JP 2021525229 A JP2021525229 A JP 2021525229A JP 7471291 B2 JP7471291 B2 JP 7471291B2
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethyl
- oxabicyclo
- phenyl
- hydroxy
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001939 inductive effect Effects 0.000 title claims description 18
- 206010060820 Joint injury Diseases 0.000 title claims description 16
- 230000022159 cartilage development Effects 0.000 title claims description 11
- RSBJUAXUHBGHBC-UHFFFAOYSA-N 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical class OC1C2CC(C(C1)O2)C(=O)N RSBJUAXUHBGHBC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 208
- 238000000034 method Methods 0.000 claims description 149
- 239000000203 mixture Substances 0.000 claims description 110
- 150000003839 salts Chemical class 0.000 claims description 81
- 230000006378 damage Effects 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 39
- 210000001503 joint Anatomy 0.000 claims description 39
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 37
- 210000001612 chondrocyte Anatomy 0.000 claims description 37
- 206010003246 arthritis Diseases 0.000 claims description 35
- -1 chloro, methyl Chemical group 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 32
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- 210000000845 cartilage Anatomy 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 20
- 230000004069 differentiation Effects 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 210000003035 hyaline cartilage Anatomy 0.000 claims description 16
- 230000008439 repair process Effects 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- AIYDLTREJPNUNU-PNKHAZJDSA-N (1R,2R,3S,4R,5S)-5-hydroxy-3-(2-methylpyridin-4-yl)-N-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound O[C@@H]1[C@H]2[C@@H]([C@H]([C@@H](C1)O2)C(=O)NC1=CC(=CC=C1)C(F)(F)F)C1=CC(=NC=C1)C AIYDLTREJPNUNU-PNKHAZJDSA-N 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 111
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 64
- 238000005160 1H NMR spectroscopy Methods 0.000 description 63
- 238000005481 NMR spectroscopy Methods 0.000 description 49
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000004808 supercritical fluid chromatography Methods 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 230000014759 maintenance of location Effects 0.000 description 19
- 229910052805 deuterium Inorganic materials 0.000 description 18
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 201000008482 osteoarthritis Diseases 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 238000010348 incorporation Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- NKQAMXOUNPVERU-RRKCRQDMSA-N methyl (1R,4R,5S)-5-hydroxy-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylate Chemical compound O[C@@H]1[C@H]2C=C([C@@H](C1)O2)C(=O)OC NKQAMXOUNPVERU-RRKCRQDMSA-N 0.000 description 8
- FIYSWKITUMBNQB-UHFFFAOYSA-N methyl 3-bromo-7-oxabicyclo[2.2.1]hepta-2,5-diene-2-carboxylate Chemical compound BrC1=C(C2C=CC1O2)C(=O)OC FIYSWKITUMBNQB-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- IAIRNHIXDCZUCV-UHFFFAOYSA-N 2-amino-4-(trifluoromethyl)benzonitrile Chemical compound NC1=CC(C(F)(F)F)=CC=C1C#N IAIRNHIXDCZUCV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 206010007710 Cartilage injury Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- KITGEMDAROEPQW-UHFFFAOYSA-N 5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-N-[4-(trifluoromethyl)pyridin-2-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound OC1C2C(C(C(C1)O2)C(=O)NC1=NC=CC(=C1)C(F)(F)F)C=1C(=NN(C=1)C)C(F)(F)F KITGEMDAROEPQW-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 4
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 4
- NXLJYICPRAMRQY-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2C(F)(F)F)=NC=C2Cl)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2C(F)(F)F)=NC=C2Cl)=O)=C1 NXLJYICPRAMRQY-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- VTHHCPMWBUGLPI-UHFFFAOYSA-N N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-(2-methoxypyridin-4-yl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound COC1=NC=CC(=C1)C2C(C3CC(C2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C#N VTHHCPMWBUGLPI-UHFFFAOYSA-N 0.000 description 4
- GKKMWYPPJBZBTH-UHFFFAOYSA-N N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound C(#N)C1=C(C=C(C=C1)C(F)(F)F)NC(=O)C1C2CC(C(C1C=1C(=NN(C=1)C)C(F)(F)F)O2)O GKKMWYPPJBZBTH-UHFFFAOYSA-N 0.000 description 4
- BFFTYRILEHLYDO-UHFFFAOYSA-N N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound C1C(C2C(C(C1O2)C(=O)NC3=C(C=CC(=C3)C(F)(F)F)C#N)C4=CC(=CC=C4)C(F)(F)F)O BFFTYRILEHLYDO-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010048873 Traumatic arthritis Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- BWAWGZUMTXRMNA-UHFFFAOYSA-N N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C(=CC(=N1)C(F)(F)F)C2C(C3CC(C2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C#N BWAWGZUMTXRMNA-UHFFFAOYSA-N 0.000 description 3
- OURSPUYWWBBMMC-UHFFFAOYSA-N N-[6-chloro-5-(trifluoromethyl)pyridin-2-yl]-5-hydroxy-3-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound C1C(C2C(C(C1O2)C(=O)NC3=NC(=C(C=C3)C(F)(F)F)Cl)C4=CC(=CC=C4)C(F)(F)F)O OURSPUYWWBBMMC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- CQDVLGWMGVDHFS-XIVJJUGBSA-N methyl (1R,4S,5S)-3-bromo-5-hydroxy-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylate Chemical compound [C@H]1(O)C[C@@H]2C(=C(Br)[C@H]1O2)C(=O)OC CQDVLGWMGVDHFS-XIVJJUGBSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- KITGEMDAROEPQW-MYALOSSISA-N (1R,2R,3S,4R,5S)-5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-N-[4-(trifluoromethyl)pyridin-2-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C=C(C(=N1)C(F)(F)F)[C@@H]2[C@H]([C@H]3C[C@@H]([C@@H]2O3)O)C(=O)NC4=NC=CC(=C4)C(F)(F)F KITGEMDAROEPQW-MYALOSSISA-N 0.000 description 2
- VTHHCPMWBUGLPI-XJWCYLOLSA-N (1R,2R,3S,4R,5S)-N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-(2-methoxypyridin-4-yl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound COC1=NC=CC(=C1)[C@@H]2[C@H]([C@H]3C[C@@H]([C@@H]2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C#N VTHHCPMWBUGLPI-XJWCYLOLSA-N 0.000 description 2
- GKKMWYPPJBZBTH-OTJKEOIZSA-N (1R,2R,3S,4R,5S)-N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C=C(C(=N1)C(F)(F)F)[C@@H]2[C@H]([C@H]3C[C@@H]([C@@H]2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C#N GKKMWYPPJBZBTH-OTJKEOIZSA-N 0.000 description 2
- BWAWGZUMTXRMNA-DRBLLZIRSA-N (1R,2R,3S,4R,5S)-N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C(=CC(=N1)C(F)(F)F)[C@@H]2[C@H]([C@H]3C[C@@H]([C@@H]2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C#N BWAWGZUMTXRMNA-DRBLLZIRSA-N 0.000 description 2
- BFFTYRILEHLYDO-JKEDJMADSA-N (1R,2R,3S,4R,5S)-N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound C1[C@@H]([C@H]2[C@@H]([C@H]([C@@H]1O2)C(=O)NC3=C(C=CC(=C3)C(F)(F)F)C#N)C4=CC(=CC=C4)C(F)(F)F)O BFFTYRILEHLYDO-JKEDJMADSA-N 0.000 description 2
- OURSPUYWWBBMMC-RIMJYPKNSA-N (1R,2R,3S,4R,5S)-N-[6-chloro-5-(trifluoromethyl)pyridin-2-yl]-5-hydroxy-3-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound C1[C@@H]([C@H]2[C@@H]([C@H]([C@@H]1O2)C(=O)NC3=NC(=C(C=C3)C(F)(F)F)Cl)C4=CC(=CC=C4)C(F)(F)F)O OURSPUYWWBBMMC-RIMJYPKNSA-N 0.000 description 2
- BWAWGZUMTXRMNA-PNDGYWDASA-N (1S,2S,3R,4S,5R)-N-[2-cyano-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C(=CC(=N1)C(F)(F)F)[C@H]2[C@@H]([C@@H]3C[C@H]([C@H]2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C#N BWAWGZUMTXRMNA-PNDGYWDASA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- SLUINPGXGFUMLL-UHFFFAOYSA-N 2-[(4-phenylphenyl)carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C=CC=CC=2)C=C1 SLUINPGXGFUMLL-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BYUQXDRAVOSANH-UHFFFAOYSA-N 5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-N-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound OC1C2C(C(C(C1)O2)C(=O)NC1=CC(=CC=C1)C(F)(F)F)C=1C(=NN(C=1)C)C(F)(F)F BYUQXDRAVOSANH-UHFFFAOYSA-N 0.000 description 2
- IZHJYTGQSSSRJY-UHFFFAOYSA-N 5-hydroxy-N-[2-methoxy-5-(trifluoromethyl)phenyl]-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C=C(C(=N1)C(F)(F)F)C2C(C3CC(C2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)OC IZHJYTGQSSSRJY-UHFFFAOYSA-N 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010071155 Autoimmune arthritis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- GKKMWYPPJBZBTH-LYYZXLFJSA-N CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C(C(F)(F)F)C=C2)=C2C#N)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C(C(F)(F)F)C=C2)=C2C#N)=O)=C1 GKKMWYPPJBZBTH-LYYZXLFJSA-N 0.000 description 2
- KITGEMDAROEPQW-JPKGWIMLSA-N CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC2=NC=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC2=NC=CC(C(F)(F)F)=C2)=O)=C1 KITGEMDAROEPQW-JPKGWIMLSA-N 0.000 description 2
- NXLJYICPRAMRQY-MYALOSSISA-N CN1N=C(C(F)(F)F)C([C@H]2[C@H]([C@H](C3)O)O[C@H]3[C@@H]2C(NC(C=C2C(F)(F)F)=NC=C2Cl)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C([C@H]2[C@H]([C@H](C3)O)O[C@H]3[C@@H]2C(NC(C=C2C(F)(F)F)=NC=C2Cl)=O)=C1 NXLJYICPRAMRQY-MYALOSSISA-N 0.000 description 2
- VTHHCPMWBUGLPI-UWAKZDDMSA-N COC1=NC=CC([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C(C(F)(F)F)C=C2)=C2C#N)=O)=C1 Chemical compound COC1=NC=CC([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C(C(F)(F)F)C=C2)=C2C#N)=O)=C1 VTHHCPMWBUGLPI-UWAKZDDMSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 206010065433 Ligament rupture Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- BFFTYRILEHLYDO-ICBNADEASA-N N#CC(C=CC(C(F)(F)F)=C1)=C1NC([C@H]([C@H](C1)O[C@@H]2[C@@H]1O)[C@@H]2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound N#CC(C=CC(C(F)(F)F)=C1)=C1NC([C@H]([C@H](C1)O[C@@H]2[C@@H]1O)[C@@H]2C1=CC(C(F)(F)F)=CC=C1)=O BFFTYRILEHLYDO-ICBNADEASA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 235000008673 Persea americana Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 208000015100 cartilage disease Diseases 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000011227 chondrocyte hypertrophy Effects 0.000 description 2
- AHMIRVCNZZUANP-LPBAWZRYSA-N chrysalin Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)N)C1=CC=CC=C1.C([C@@H](C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)N)C1=CC=CC=C1.C([C@@H](C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)N)C1=CC=CC=C1 AHMIRVCNZZUANP-LPBAWZRYSA-N 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000018180 degenerative disc disease Diseases 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 2
- 229940017219 methyl propionate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 108010018091 rusalatide acetate Proteins 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BYUQXDRAVOSANH-QRTUWBSPSA-N (1R,2R,3S,4R,5S)-5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-N-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C=C(C(=N1)C(F)(F)F)[C@@H]2[C@H]([C@H]3C[C@@H]([C@@H]2O3)O)C(=O)NC4=CC=CC(=C4)C(F)(F)F BYUQXDRAVOSANH-QRTUWBSPSA-N 0.000 description 1
- IZHJYTGQSSSRJY-AMMHQNNLSA-N (1R,2R,3S,4R,5S)-5-hydroxy-N-[2-methoxy-5-(trifluoromethyl)phenyl]-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1C=C(C(=N1)C(F)(F)F)[C@@H]2[C@H]([C@H]3C[C@@H]([C@@H]2O3)O)C(=O)NC4=C(C=CC(=C4)C(F)(F)F)OC IZHJYTGQSSSRJY-AMMHQNNLSA-N 0.000 description 1
- JBBWIOOUTUWSMJ-FSDCSDTHSA-N (1R,2R,3S,4S)-3-(2-aminopyridin-4-yl)-N-(3,4-dichlorophenyl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound NC1=NC=CC(=C1)[C@@H]1[C@H]([C@H]2CC[C@@H]1O2)C(=O)NC2=CC(=C(C=C2)Cl)Cl JBBWIOOUTUWSMJ-FSDCSDTHSA-N 0.000 description 1
- HNLJEOAFXYIQQM-YVSFHVDLSA-N (1R,2R,3S,4S)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@H]1[C@H]2CC[C@@H]([C@@H]1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-YVSFHVDLSA-N 0.000 description 1
- ATFFWCIMTHMCPI-QFHJOOASSA-N (1R,2R,4S,5S)-N-(3,4-dichlorophenyl)-4-pyridin-4-yl-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@]12[C@H]3CC[C@@H]([C@@]2(C1)C1=CC=NC=C1)O3 ATFFWCIMTHMCPI-QFHJOOASSA-N 0.000 description 1
- PAIQAKBTYYBSKX-SJXGUFTOSA-N (1R,2S,3R,4S)-N-(3,4-dichlorophenyl)-3-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@@H]1[C@H]2CC[C@@H]([C@H]1C1=CC(=NN1C)C(F)(F)F)O2 PAIQAKBTYYBSKX-SJXGUFTOSA-N 0.000 description 1
- HNLJEOAFXYIQQM-VVLHAWIVSA-N (1R,2S,3S,4S)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@@H]1[C@H]2CC[C@@H]([C@@H]1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-VVLHAWIVSA-N 0.000 description 1
- HNLJEOAFXYIQQM-TWMKSMIVSA-N (1S,2R,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@H]1[C@@H]2CC[C@H]([C@H]1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-TWMKSMIVSA-N 0.000 description 1
- JBBWIOOUTUWSMJ-YALNPMBYSA-N (1S,2S,3R,4R)-3-(2-aminopyridin-4-yl)-N-(3,4-dichlorophenyl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound NC1=NC=CC(=C1)[C@H]1[C@@H]([C@@H]2CC[C@H]1O2)C(=O)NC2=CC(=C(C=C2)Cl)Cl JBBWIOOUTUWSMJ-YALNPMBYSA-N 0.000 description 1
- HNLJEOAFXYIQQM-YYIAUSFCSA-N (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@@H]1[C@@H]2CC[C@H]([C@H]1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-YYIAUSFCSA-N 0.000 description 1
- BYUQXDRAVOSANH-GZBLMMOJSA-N (1S,2S,3R,4S,5R)-5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-N-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC2=CC(C(F)(F)F)=CC=C2)=O)=C1 BYUQXDRAVOSANH-GZBLMMOJSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical group COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RWGBXAQMUBGGKQ-UHFFFAOYSA-N 4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC(C(F)(F)F)=CC=N1 RWGBXAQMUBGGKQ-UHFFFAOYSA-N 0.000 description 1
- LLARVKAOQLUCQI-UHFFFAOYSA-L 4-benzamido-2,5-dimethoxybenzenediazonium;tetrachlorozinc(2-) Chemical compound [Cl-].[Cl-].Cl[Zn]Cl.COC1=CC([N+]#N)=C(OC)C=C1NC(=O)C1=CC=CC=C1.COC1=CC([N+]#N)=C(OC)C=C1NC(=O)C1=CC=CC=C1 LLARVKAOQLUCQI-UHFFFAOYSA-L 0.000 description 1
- RVHOCQUEFYITIV-UHFFFAOYSA-N 5-chloro-4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC(C(F)(F)F)=C(Cl)C=N1 RVHOCQUEFYITIV-UHFFFAOYSA-N 0.000 description 1
- RYIGNEOBDRVTHA-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2 RYIGNEOBDRVTHA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BELOBXJMTWHNNN-UHFFFAOYSA-N CC(C(C(F)(F)F)=CC=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound CC(C(C(F)(F)F)=CC=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O BELOBXJMTWHNNN-UHFFFAOYSA-N 0.000 description 1
- IOCYRANOEZEOIA-UHFFFAOYSA-N CC(C(C(F)(F)F)=CC=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O Chemical compound CC(C(C(F)(F)F)=CC=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O IOCYRANOEZEOIA-UHFFFAOYSA-N 0.000 description 1
- YFPAEDHXOWYOCP-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2C#N)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2C#N)=O)=C1 YFPAEDHXOWYOCP-UHFFFAOYSA-N 0.000 description 1
- BCGYEMNBGSNEJQ-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2F)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2F)=O)=C1 BCGYEMNBGSNEJQ-UHFFFAOYSA-N 0.000 description 1
- QXMNHLGFWNZKIP-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=C(C)C=C2)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=C(C)C=C2)=O)=C1 QXMNHLGFWNZKIP-UHFFFAOYSA-N 0.000 description 1
- PXJPWDXCYHQTAE-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=CC=C2)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=CC=C2)=O)=C1 PXJPWDXCYHQTAE-UHFFFAOYSA-N 0.000 description 1
- HJMANTKJJDAPBF-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C)=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C)=CC(C(F)(F)F)=C2)=O)=C1 HJMANTKJJDAPBF-UHFFFAOYSA-N 0.000 description 1
- NZABGYCXQNGMOU-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=C(C(F)(F)F)C=C2)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=C(C(F)(F)F)C=C2)=O)=C1 NZABGYCXQNGMOU-UHFFFAOYSA-N 0.000 description 1
- WTIRPKFHSKETHS-UHFFFAOYSA-N CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=NC=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CC(C)N1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=NC=CC(C(F)(F)F)=C2)=O)=C1 WTIRPKFHSKETHS-UHFFFAOYSA-N 0.000 description 1
- SBFDFDRHUUIILW-UHFFFAOYSA-N CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O SBFDFDRHUUIILW-UHFFFAOYSA-N 0.000 description 1
- FTDWNWYYEUTMBQ-UHFFFAOYSA-N CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=NC=C1)=O Chemical compound CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=NC=C1)=O FTDWNWYYEUTMBQ-UHFFFAOYSA-N 0.000 description 1
- XCNFQFXYWHPQEA-UHFFFAOYSA-N CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=NN1C)=O Chemical compound CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=NN1C)=O XCNFQFXYWHPQEA-UHFFFAOYSA-N 0.000 description 1
- UPRWMPZGSYPQLV-UHFFFAOYSA-N CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(OC)=NC=C1)=O Chemical compound CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(OC)=NC=C1)=O UPRWMPZGSYPQLV-UHFFFAOYSA-N 0.000 description 1
- YMWLVLHHAMBCAM-UHFFFAOYSA-N CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O Chemical compound CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O YMWLVLHHAMBCAM-UHFFFAOYSA-N 0.000 description 1
- MASUTRQCOBGHNO-UHFFFAOYSA-N CC(C=CC(C(F)(F)F)=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound CC(C=CC(C(F)(F)F)=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O MASUTRQCOBGHNO-UHFFFAOYSA-N 0.000 description 1
- MOJFKFHUUBGXHY-UHFFFAOYSA-N CC(C=CC(C(F)(F)F)=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O Chemical compound CC(C=CC(C(F)(F)F)=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O MOJFKFHUUBGXHY-UHFFFAOYSA-N 0.000 description 1
- KJXZIPXBZQIBQS-UHFFFAOYSA-N CC1=C(C(F)(F)F)N=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 Chemical compound CC1=C(C(F)(F)F)N=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 KJXZIPXBZQIBQS-UHFFFAOYSA-N 0.000 description 1
- TVINOCQVYQUIBQ-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 TVINOCQVYQUIBQ-UHFFFAOYSA-N 0.000 description 1
- BLOCOUZVTXGIDR-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=N1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=N1 BLOCOUZVTXGIDR-UHFFFAOYSA-N 0.000 description 1
- CVJNXASKHMUOJG-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=NC=C2)=O)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=NC=C2)=O)=C1 CVJNXASKHMUOJG-UHFFFAOYSA-N 0.000 description 1
- NTVPNRRMHGCYMI-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=NN2C)=O)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=NN2C)=O)=C1 NTVPNRRMHGCYMI-UHFFFAOYSA-N 0.000 description 1
- UINARKRIFDAHOL-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(OC)=NC=C2)=O)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(OC)=NC=C2)=O)=C1 UINARKRIFDAHOL-UHFFFAOYSA-N 0.000 description 1
- XOEJRUKQSQQBSW-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CN(C)N=C2C(F)(F)F)=O)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CN(C)N=C2C(F)(F)F)=O)=C1 XOEJRUKQSQQBSW-UHFFFAOYSA-N 0.000 description 1
- OMXAAEHZTOGIDM-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CN(C)N=C2C(F)(F)F)=O)=N1 Chemical compound CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CN(C)N=C2C(F)(F)F)=O)=N1 OMXAAEHZTOGIDM-UHFFFAOYSA-N 0.000 description 1
- QMAWPQZUSPPGNV-UHFFFAOYSA-N CCOC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound CCOC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O QMAWPQZUSPPGNV-UHFFFAOYSA-N 0.000 description 1
- VSLGNPFCYDPPDY-UHFFFAOYSA-N CCOC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=N1 Chemical compound CCOC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=N1 VSLGNPFCYDPPDY-UHFFFAOYSA-N 0.000 description 1
- MROGIAUJCYZNLL-UHFFFAOYSA-N CCOC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CN(C)N=C2C(F)(F)F)=O)=N1 Chemical compound CCOC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CN(C)N=C2C(F)(F)F)=O)=N1 MROGIAUJCYZNLL-UHFFFAOYSA-N 0.000 description 1
- DCZSTRCHJSQWGW-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2F)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2F)=O)=C1 DCZSTRCHJSQWGW-UHFFFAOYSA-N 0.000 description 1
- QUYVOSNOMKEQML-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)=C1 QUYVOSNOMKEQML-UHFFFAOYSA-N 0.000 description 1
- DFIIKXZHCXOKJY-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2Cl)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2Cl)=O)=C1 DFIIKXZHCXOKJY-UHFFFAOYSA-N 0.000 description 1
- GVZDUURSMUYZBC-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2F)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2F)=O)=C1 GVZDUURSMUYZBC-UHFFFAOYSA-N 0.000 description 1
- NELITTFSRVNSCL-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2N2CCOCC2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2N2CCOCC2)=O)=C1 NELITTFSRVNSCL-UHFFFAOYSA-N 0.000 description 1
- CJTJVXJVUUOYPI-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2OC)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=C2)=CC(C(F)(F)F)=C2OC)=O)=C1 CJTJVXJVUUOYPI-UHFFFAOYSA-N 0.000 description 1
- DXQVVUAMGWAXEP-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=CC=C2C(F)(F)F)=C2F)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC(C=CC=C2C(F)(F)F)=C2F)=O)=C1 DXQVVUAMGWAXEP-UHFFFAOYSA-N 0.000 description 1
- MGNVSBYGECLWMX-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)=C1 MGNVSBYGECLWMX-UHFFFAOYSA-N 0.000 description 1
- AMZRNPCLFTWUPO-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=C(C(F)(F)F)C=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=C(C(F)(F)F)C=C2)=O)=C1 AMZRNPCLFTWUPO-UHFFFAOYSA-N 0.000 description 1
- YUJQOJBLKMTBPM-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=CC(C(F)(F)F)=C2)=O)=C1 YUJQOJBLKMTBPM-UHFFFAOYSA-N 0.000 description 1
- KSYHUJJLFNHCMO-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(F)=C(C(F)(F)F)C=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(F)=C(C(F)(F)F)C=C2)=O)=C1 KSYHUJJLFNHCMO-UHFFFAOYSA-N 0.000 description 1
- PKUNHCNCUKMKTK-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(F)=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC(F)=CC(C(F)(F)F)=C2)=O)=C1 PKUNHCNCUKMKTK-UHFFFAOYSA-N 0.000 description 1
- DDFQZOVIVBGZTQ-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC=C(C(F)(F)F)C=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=CC=C(C(F)(F)F)C=C2)=O)=C1 DDFQZOVIVBGZTQ-UHFFFAOYSA-N 0.000 description 1
- IYSPSAATAIOHNF-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=NC(C3CC3)=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=NC(C3CC3)=CC(C(F)(F)F)=C2)=O)=C1 IYSPSAATAIOHNF-UHFFFAOYSA-N 0.000 description 1
- UOALROLFNXGHDP-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=NC(Cl)=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C(C2C(C(C3)O)OC3C2C(NC2=NC(Cl)=CC(C(F)(F)F)=C2)=O)=C1 UOALROLFNXGHDP-UHFFFAOYSA-N 0.000 description 1
- IZHJYTGQSSSRJY-DZQJYWQESA-N CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C(C(F)(F)F)C=C2)=C2OC)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C(C(F)(F)F)C=C2)=C2OC)=O)=C1 IZHJYTGQSSSRJY-DZQJYWQESA-N 0.000 description 1
- NXLJYICPRAMRQY-JPKGWIMLSA-N CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C2C(F)(F)F)=NC=C2Cl)=O)=C1 Chemical compound CN1N=C(C(F)(F)F)C([C@@H]2[C@@H]([C@@H](C3)O)O[C@@H]3[C@H]2C(NC(C=C2C(F)(F)F)=NC=C2Cl)=O)=C1 NXLJYICPRAMRQY-JPKGWIMLSA-N 0.000 description 1
- CZRKAPWGSHYAGO-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC(C=C(C(F)(F)F)C=C1)=C1F)=O Chemical compound CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC(C=C(C(F)(F)F)C=C1)=C1F)=O CZRKAPWGSHYAGO-UHFFFAOYSA-N 0.000 description 1
- YYPFEPKHVJTBBG-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=CC(C(F)(F)F)=CC=C1)=O YYPFEPKHVJTBBG-UHFFFAOYSA-N 0.000 description 1
- ANVPWGXFACOKOP-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=CC(Cl)=C(C(F)(F)F)C=C1)=O Chemical compound CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=CC(Cl)=C(C(F)(F)F)C=C1)=O ANVPWGXFACOKOP-UHFFFAOYSA-N 0.000 description 1
- OQPKSTCPIYVRFJ-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=CC=C(C(F)(F)F)C=C1)=O Chemical compound CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=CC=C(C(F)(F)F)C=C1)=O OQPKSTCPIYVRFJ-UHFFFAOYSA-N 0.000 description 1
- CYOMSVIQMMMJIZ-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=NC=CC(C(F)(F)F)=C1)=O Chemical compound CN1N=C(C(F)(F)F)C=C1C1C(C(C2)O)OC2C1C(NC1=NC=CC(C(F)(F)F)=C1)=O CYOMSVIQMMMJIZ-UHFFFAOYSA-N 0.000 description 1
- VYEBDJWXJGCFNO-UHFFFAOYSA-N COC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound COC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O VYEBDJWXJGCFNO-UHFFFAOYSA-N 0.000 description 1
- FZVLKLBPYDXUEM-UHFFFAOYSA-N COC(C=CC(C(F)(F)F)=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound COC(C=CC(C(F)(F)F)=C1)=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O FZVLKLBPYDXUEM-UHFFFAOYSA-N 0.000 description 1
- YWRXMWYGGPFUSI-UHFFFAOYSA-N COC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 Chemical compound COC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 YWRXMWYGGPFUSI-UHFFFAOYSA-N 0.000 description 1
- GKTOQOCNMGDJSI-UHFFFAOYSA-N COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2F)=O)=C1 Chemical compound COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC(C=C(C(F)(F)F)C=C2)=C2F)=O)=C1 GKTOQOCNMGDJSI-UHFFFAOYSA-N 0.000 description 1
- FKLSZIDAPOLLJQ-UHFFFAOYSA-N COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=CC=C2)=O)=C1 Chemical compound COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=CC(C(F)(F)F)=CC=C2)=O)=C1 FKLSZIDAPOLLJQ-UHFFFAOYSA-N 0.000 description 1
- KDCVUAWYTBQXSO-UHFFFAOYSA-N COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=C(C(F)(F)F)C=C2)=O)=C1 Chemical compound COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=CC(Cl)=C(C(F)(F)F)C=C2)=O)=C1 KDCVUAWYTBQXSO-UHFFFAOYSA-N 0.000 description 1
- JKLQMBWWICXVEU-UHFFFAOYSA-N COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=CC=C(C(F)(F)F)C=C2)=O)=C1 Chemical compound COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=CC=C(C(F)(F)F)C=C2)=O)=C1 JKLQMBWWICXVEU-UHFFFAOYSA-N 0.000 description 1
- GVRLCXKCGYFLLU-UHFFFAOYSA-N COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=NC=CC(C(F)(F)F)=C2)=O)=C1 Chemical compound COC1=NC=CC(C2C(C(C3)O)OC3C2C(NC2=NC=CC(C(F)(F)F)=C2)=O)=C1 GVRLCXKCGYFLLU-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- LKOYFWPMKRXQTI-UHFFFAOYSA-N FC1=CC=CC=C1C1=CC=C(NC(=O)C2=C(C3CCC2O3)C2=CN=CC=N2)C=C1F Chemical compound FC1=CC=CC=C1C1=CC=C(NC(=O)C2=C(C3CCC2O3)C2=CN=CC=N2)C=C1F LKOYFWPMKRXQTI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000002658 Intra-Articular Fractures Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- ZETLQLOPXFBVEN-UHFFFAOYSA-N N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CC(C(F)(F)F)=CC=C1)=O ZETLQLOPXFBVEN-UHFFFAOYSA-N 0.000 description 1
- RWWQNNTVQWEFOB-UHFFFAOYSA-N N#CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 Chemical compound N#CC1=CC(C(F)(F)F)=CC(NC(C(C(C2)OC3C2O)C3C2=CC(C(F)(F)F)=CC=C2)=O)=C1 RWWQNNTVQWEFOB-UHFFFAOYSA-N 0.000 description 1
- PTBQSSZDCKBRMM-UHFFFAOYSA-N N-[2-fluoro-5-(trifluoromethyl)phenyl]-5-hydroxy-3-[3-(trifluoromethyl)phenyl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound FC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C1C2CC(C(C1C1=CC(=CC=C1)C(F)(F)F)O2)O PTBQSSZDCKBRMM-UHFFFAOYSA-N 0.000 description 1
- QVZCRCLUXZPFBD-UHFFFAOYSA-N N-[3-chloro-4-(2-fluorophenyl)phenyl]-3-(1H-pyrazol-5-yl)-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxamide Chemical compound FC1=CC=CC=C1C1=CC=C(NC(=O)C2=C(C3CCC2O3)C2=CC=NN2)C=C1Cl QVZCRCLUXZPFBD-UHFFFAOYSA-N 0.000 description 1
- JSZWMBSHUXBBDE-UHFFFAOYSA-N N-[4-ethoxy-3-(trifluoromethyl)phenyl]-5-hydroxy-3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound CCOC(C=C1)=C(C(F)(F)F)C=C1NC(C(C(C1)OC2C1O)C2C1=CN(C)N=C1C(F)(F)F)=O JSZWMBSHUXBBDE-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- BNYGYXKXJZGYSU-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1)=CC(C(F)(F)F)=C1Cl)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1)=CC(C(F)(F)F)=C1Cl)=O BNYGYXKXJZGYSU-UHFFFAOYSA-N 0.000 description 1
- KXVPUEJJQACHGX-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1)=CC(C(F)(F)F)=C1F)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1)=CC(C(F)(F)F)=C1F)=O KXVPUEJJQACHGX-UHFFFAOYSA-N 0.000 description 1
- CKIPCXIVZDGLQQ-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1)=CC(C(F)(F)F)=C1N1CCOCC1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1)=CC(C(F)(F)F)=C1N1CCOCC1)=O CKIPCXIVZDGLQQ-UHFFFAOYSA-N 0.000 description 1
- ARHRSXDVKLBYTC-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1C(F)(F)F)=NC=C1Cl)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=C1C(F)(F)F)=NC=C1Cl)=O ARHRSXDVKLBYTC-UHFFFAOYSA-N 0.000 description 1
- ZKNHAIOYDUITCZ-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=CC=C1C(F)(F)F)=C1F)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC(C=CC=C1C(F)(F)F)=C1F)=O ZKNHAIOYDUITCZ-UHFFFAOYSA-N 0.000 description 1
- CNXNGXBXTSLDBR-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O CNXNGXBXTSLDBR-UHFFFAOYSA-N 0.000 description 1
- VPLFPTBCUWAFBC-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(Cl)=C(C(F)(F)F)C=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(Cl)=C(C(F)(F)F)C=C1)=O VPLFPTBCUWAFBC-UHFFFAOYSA-N 0.000 description 1
- FQQBIAVEGCHSDN-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(Cl)=CC(C(F)(F)F)=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(Cl)=CC(C(F)(F)F)=C1)=O FQQBIAVEGCHSDN-UHFFFAOYSA-N 0.000 description 1
- ZRNNTNOJVIEVEV-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(F)=C(C(F)(F)F)C=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(F)=C(C(F)(F)F)C=C1)=O ZRNNTNOJVIEVEV-UHFFFAOYSA-N 0.000 description 1
- ICJGBWIUIHTVGR-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(F)=CC(C(F)(F)F)=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC(F)=CC(C(F)(F)F)=C1)=O ICJGBWIUIHTVGR-UHFFFAOYSA-N 0.000 description 1
- CBBQVPFRZLLFIX-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC=C(C(F)(F)F)N=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=CC=C(C(F)(F)F)N=C1)=O CBBQVPFRZLLFIX-UHFFFAOYSA-N 0.000 description 1
- DFKDKFSTGGQONC-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC(C2CC2)=CC(C(F)(F)F)=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC(C2CC2)=CC(C(F)(F)F)=C1)=O DFKDKFSTGGQONC-UHFFFAOYSA-N 0.000 description 1
- ZRUOROOCMGATSO-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC(Cl)=CC(C(F)(F)F)=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC(Cl)=CC(C(F)(F)F)=C1)=O ZRUOROOCMGATSO-UHFFFAOYSA-N 0.000 description 1
- KBHCWWVHRJNSSN-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC=C(C(F)(F)F)C=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC=C(C(F)(F)F)C=C1)=O KBHCWWVHRJNSSN-UHFFFAOYSA-N 0.000 description 1
- SXSOGVZKBQICNK-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC=CC(C(F)(F)F)=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CC=C3)OC1C2C(NC1=NC=CC(C(F)(F)F)=C1)=O SXSOGVZKBQICNK-UHFFFAOYSA-N 0.000 description 1
- YXNNTMVPMSKFAR-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=CN=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=CN=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O YXNNTMVPMSKFAR-UHFFFAOYSA-N 0.000 description 1
- SFKRXMUUOJYASE-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=NC=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=NC=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O SFKRXMUUOJYASE-UHFFFAOYSA-N 0.000 description 1
- HKNHZZCGKRAVPD-UHFFFAOYSA-N OC(C1)C(C2C3=CC(C(F)(F)F)=NC=C3)OC1C2C(NC1=CC=C(C(F)(F)F)C=C1)=O Chemical compound OC(C1)C(C2C3=CC(C(F)(F)F)=NC=C3)OC1C2C(NC1=CC=C(C(F)(F)F)C=C1)=O HKNHZZCGKRAVPD-UHFFFAOYSA-N 0.000 description 1
- JDOHXCDSNQROKQ-UHFFFAOYSA-N OC(C1)C(C2C3=CC(F)=NC=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound OC(C1)C(C2C3=CC(F)=NC=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O JDOHXCDSNQROKQ-UHFFFAOYSA-N 0.000 description 1
- WNHUPLNUYCCNDZ-UHFFFAOYSA-N OC(C1)C(C2C3=CC=C(C(F)(F)F)N=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound OC(C1)C(C2C3=CC=C(C(F)(F)F)N=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O WNHUPLNUYCCNDZ-UHFFFAOYSA-N 0.000 description 1
- GMUBBWANTACZRZ-UHFFFAOYSA-N OC(C1)C(C2C3=CN=C(C(F)(F)F)N=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O Chemical compound OC(C1)C(C2C3=CN=C(C(F)(F)F)N=C3)OC1C2C(NC1=CC(C(F)(F)F)=CC=C1)=O GMUBBWANTACZRZ-UHFFFAOYSA-N 0.000 description 1
- OURSPUYWWBBMMC-XVLPMQGWSA-N O[C@H](C1)[C@H]([C@H]2C3=CC(C(F)(F)F)=CC=C3)O[C@@H]1[C@H]2C(NC1=NC(Cl)=C(C(F)(F)F)C=C1)=O Chemical compound O[C@H](C1)[C@H]([C@H]2C3=CC(C(F)(F)F)=CC=C3)O[C@@H]1[C@H]2C(NC1=NC(Cl)=C(C(F)(F)F)C=C1)=O OURSPUYWWBBMMC-XVLPMQGWSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 208000023835 Tendon disease Diseases 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- IOMLBTHPCVDRHM-UHFFFAOYSA-N [3-[(2,4-dimethylphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=CC2=CC=CC=C2C=C1OP(O)(O)=O IOMLBTHPCVDRHM-UHFFFAOYSA-N 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000008063 acylals Chemical class 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010927 atrophic thyroiditis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000019748 bullous skin disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940068190 chlorotheophylline Drugs 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000007256 debromination reaction Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000007192 granulomatous hepatitis Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical group COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776267P | 2018-12-06 | 2018-12-06 | |
| US62/776,267 | 2018-12-06 | ||
| PCT/IB2019/060454 WO2020115683A1 (en) | 2018-12-06 | 2019-12-04 | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022509765A JP2022509765A (ja) | 2022-01-24 |
| JP2022509765A5 JP2022509765A5 (https=) | 2022-12-12 |
| JPWO2020115683A5 JPWO2020115683A5 (https=) | 2022-12-12 |
| JP7471291B2 true JP7471291B2 (ja) | 2024-04-19 |
Family
ID=68916501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525229A Active JP7471291B2 (ja) | 2018-12-06 | 2019-12-04 | 関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12257243B2 (https=) |
| EP (1) | EP3891154B1 (https=) |
| JP (1) | JP7471291B2 (https=) |
| CN (1) | CN113015735B (https=) |
| ES (1) | ES2963508T3 (https=) |
| WO (1) | WO2020115683A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113015735B (zh) | 2018-12-06 | 2024-06-21 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物 |
| ES2965684T3 (es) | 2018-12-06 | 2024-04-16 | Novartis Ag | Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004505048A (ja) | 2000-08-01 | 2004-02-19 | ユニバーシティー オブ ヴァージニア パテント ファウンデーション | 血管新生を処理するための、選択的アデノシンａ１受容体アゴニスト、アンタゴニストおよびアロステリックエンハンサーの使用 |
| WO2007130353A2 (en) | 2006-05-01 | 2007-11-15 | Johns Hopkins University | Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress |
| JP2017519729A (ja) | 2014-05-13 | 2017-07-20 | ノバルティス アーゲー | 軟骨形成を誘導するための化合物および組成物 |
| JP2018531213A (ja) | 2015-03-13 | 2018-10-25 | フォーマ セラピューティクス，インコーポレイテッド | Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物 |
| WO2019092637A1 (en) | 2017-11-10 | 2019-05-16 | Novartis Ag | Extended release formulations for intra-articular applications |
| JP7229945B2 (ja) | 2017-06-09 | 2023-02-28 | ノバルティス アーゲー | 軟骨形成を誘導するための化合物及び組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010273570B2 (en) | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN113015735B (zh) | 2018-12-06 | 2024-06-21 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物 |
-
2019
- 2019-12-04 CN CN201980073992.1A patent/CN113015735B/zh active Active
- 2019-12-04 JP JP2021525229A patent/JP7471291B2/ja active Active
- 2019-12-04 US US17/299,189 patent/US12257243B2/en active Active
- 2019-12-04 EP EP19821288.8A patent/EP3891154B1/en active Active
- 2019-12-04 WO PCT/IB2019/060454 patent/WO2020115683A1/en not_active Ceased
- 2019-12-04 ES ES19821288T patent/ES2963508T3/es active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004505048A (ja) | 2000-08-01 | 2004-02-19 | ユニバーシティー オブ ヴァージニア パテント ファウンデーション | 血管新生を処理するための、選択的アデノシンａ１受容体アゴニスト、アンタゴニストおよびアロステリックエンハンサーの使用 |
| WO2007130353A2 (en) | 2006-05-01 | 2007-11-15 | Johns Hopkins University | Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress |
| JP2017519729A (ja) | 2014-05-13 | 2017-07-20 | ノバルティス アーゲー | 軟骨形成を誘導するための化合物および組成物 |
| JP2018531213A (ja) | 2015-03-13 | 2018-10-25 | フォーマ セラピューティクス，インコーポレイテッド | Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物 |
| JP7229945B2 (ja) | 2017-06-09 | 2023-02-28 | ノバルティス アーゲー | 軟骨形成を誘導するための化合物及び組成物 |
| WO2019092637A1 (en) | 2017-11-10 | 2019-05-16 | Novartis Ag | Extended release formulations for intra-articular applications |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220071972A1 (en) | 2022-03-10 |
| CN113015735A (zh) | 2021-06-22 |
| EP3891154A1 (en) | 2021-10-13 |
| US12257243B2 (en) | 2025-03-25 |
| CN113015735B (zh) | 2024-06-21 |
| ES2963508T3 (es) | 2024-03-27 |
| WO2020115683A1 (en) | 2020-06-11 |
| EP3891154B1 (en) | 2023-08-16 |
| JP2022509765A (ja) | 2022-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102775995B1 (ko) | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 | |
| US12209096B2 (en) | Compounds and compositions for inducing chondrogenesis | |
| JP7471291B2 (ja) | 関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体 | |
| CN106795152A (zh) | 蛋白激酶抑制剂 | |
| CN115996908A (zh) | Gpr39蛋白的拮抗剂 | |
| JP2022553284A (ja) | Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能の阻害剤 | |
| ES2965684T3 (es) | Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular | |
| HK40096806A (en) | Compounds and compositions for inducing chondrogenesis | |
| RU2775505C2 (ru) | Изохинолин-3-иловые карбоксамиды и их получение и применение | |
| HK40055222B (en) | Compounds and compositions for inducing chondrogenesis | |
| HK40055222A (en) | Compounds and compositions for inducing chondrogenesis | |
| HK40077288A (en) | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231121 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240402 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240409 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7471291 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |